Premium
Highly active antiretroviral therapy improves ESLD‐free survival in HIV‐HCV co‐infection
Author(s) -
RAGNI M. V.,
NALESNIK M. A.,
SCHILLO R.,
DANG Q.
Publication year - 2009
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2008.01935.x
Subject(s) - medicine , hazard ratio , proportional hazards model , confidence interval , hepatitis c , hepatitis c virus , seroconversion , liver disease , human immunodeficiency virus (hiv) , immunology , virus
Summary. The impact of highly active antiretroviral therapy (HAART) on progression to end‐stage liver disease (ESLD) in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co‐infection remains controversial. We studied 157 HCV+ haemophilic men (85 HIV+ and 72 HIV−), on whom dates of HIV and HCV seroconversion and clinical outcomes were known. Time to ESLD was determined by Kaplan–Meier product‐limit methods and risk factors for ESLD progression were analysed by a Cox proportional hazards model. Among HIV+ men, ESLD was more common, 17 of 85 (20.0%) than in HIV−, eight of 72 (11.1%) and median ESLD‐free survival significantly shorter, P = 0.009, hazard ratio 3.00 [95% confidence interval (CI): 1.27–7.08]. HAART treated HIV+ had longer ESLD‐free survival than HIV+ untreated, 30.3 vs. 20.0 years, P = 0.043, hazard ratio, 3.14 (95% CI: 1.27–7.08), comparable with survival in HIV− men, P = 0.13, hazard ratio 2.20 (95% CI: 0.76–2.35). Progression was unrelated to HAART toxicity ( n = 0) or HCV antiviral therapy ( n = 7). HIV+ HAART Rx and HIV− did not differ in HCV duration, age at ESLD, age at death or present, overall or AIDS mortality, all P > 0.05. These data suggest that HAART improves ESLD‐free survival, approaching that in HIV− men.